The Experts below are selected from a list of 1923024 Experts worldwide ranked by ideXlab platform
Daniel R Gomez - One of the best experts on this subject based on the ideXlab platform.
-
radiologic considerations and standardization of malignant pleural mesothelioma imaging within clinical trials consensus statement from the nci thoracic malignancy steering committee international association for the study of lung cancer mesothelioma
Journal of Thoracic Oncology, 2019Co-Authors: Ritu R Gill, Anne S Tsao, Suzanne E Dahlberg, Hedy L Kindler, William G Richards, Samuel G Armato, Roslyn J Francis, Daniel R Gomez, Andreas RimnerAbstract:Detailed guidelines pertaining to radiological assessment of malignant pleural mesothelioma are currently lacking due to the rarity of the disease, complex morphology, propensity to invade multiple planes simultaneously, and lack of specific recommendations within the radiology community about assessment, reporting, and follow-up. In March 2017, a multidisciplinary meeting of mesothelioma experts was co-sponsored by the National Cancer Institute Thoracic Malignancy Steering Committee, International Association for the Study of Lung Cancer, and the Mesothelioma Applied Research Foundation. One of the outcomes of this conference was the foundation of detailed, multidisciplinary consensus imaging and management guidelines. Here, we present the recommendations for radiologic assessment of malignant pleural mesothelioma in the setting of clinical trial enrollment. We discuss optimization of imaging parameters across modalities, standardized reporting, and response assessment within clinical trials.
-
the use of radiation therapy for the treatment of malignant pleural mesothelioma expert opinion from the national cancer institute thoracic malignancy steering committee international association for the study of lung cancer and mesothelioma Applied Research foundation
Journal of Thoracic Oncology, 2019Co-Authors: Daniel R Gomez, Alex A Adjei, Raphael Bueno, Ritu R Gill, Andreas Rimner, Charles B Simone, B John C Cho, Marc De Perrot, David H Harpole, Mary HesdorfferAbstract:Abstract Introduction Detailed guidelines regarding the use of radiation therapy for malignant pleural mesothelioma (MPM) are currently lacking because of the rarity of the disease, the wide spectrum of clinical presentations, and the paucity of high-level data on individual treatment approaches. Methods In March 2017, a multidisciplinary meeting of mesothelioma experts was cosponsored by the U.S. National Cancer Institute, International Association for the Study of Lung Cancer Research, and Mesothelioma Applied Research Foundation. Among the outcomes of this conference was the foundation of detailed, multidisciplinary consensus guidelines. Results Here we present consensus recommendations on the use of radiation therapy for MPM in three discrete scenarios: (1) hemithoracic radiation therapy to be used before or after extrapleural pneumonectomy; (2) hemithoracic radiation to be used as an adjuvant to lung-sparing procedures (i.e., without pneumonectomy); and (3) palliative radiation therapy for focal symptoms caused by the disease. We discuss appropriate simulation techniques, treatment volumes, dose fractionation regimens, and normal tissue constraints. We also assess the role of particle beam therapy, specifically, proton beam therapy, for MPM. Conclusion The recommendations provided in this consensus statement should serve as important guidelines for developing future clinical trials of treatment approaches for MPM.
Suzanne E Dahlberg - One of the best experts on this subject based on the ideXlab platform.
-
radiologic considerations and standardization of malignant pleural mesothelioma imaging within clinical trials consensus statement from the nci thoracic malignancy steering committee international association for the study of lung cancer mesothelioma
Journal of Thoracic Oncology, 2019Co-Authors: Ritu R Gill, Anne S Tsao, Suzanne E Dahlberg, Hedy L Kindler, William G Richards, Samuel G Armato, Roslyn J Francis, Daniel R Gomez, Andreas RimnerAbstract:Detailed guidelines pertaining to radiological assessment of malignant pleural mesothelioma are currently lacking due to the rarity of the disease, complex morphology, propensity to invade multiple planes simultaneously, and lack of specific recommendations within the radiology community about assessment, reporting, and follow-up. In March 2017, a multidisciplinary meeting of mesothelioma experts was co-sponsored by the National Cancer Institute Thoracic Malignancy Steering Committee, International Association for the Study of Lung Cancer, and the Mesothelioma Applied Research Foundation. One of the outcomes of this conference was the foundation of detailed, multidisciplinary consensus imaging and management guidelines. Here, we present the recommendations for radiologic assessment of malignant pleural mesothelioma in the setting of clinical trial enrollment. We discuss optimization of imaging parameters across modalities, standardized reporting, and response assessment within clinical trials.
-
current and future management of malignant mesothelioma a consensus report from the national cancer institute thoracic malignancy steering committee international association for the study of lung cancer and mesothelioma Applied Research foundation
Journal of Thoracic Oncology, 2018Co-Authors: Anne S Tsao, Wolf O Lindwasser, Alex A Adjei, Prasad S Adusumilli, Matthew L Beyers, Gideon M Blumenthal, Raphael Bueno, Bryan M Burt, Michele Carbone, Suzanne E DahlbergAbstract:On March 28- 29, 2017, the National Cancer Institute (NCI) Thoracic Malignacy Steering Committee, International Association for the Study of Lung Cancer, and Mesothelioma Applied Research Foundation convened the NCI-International Association for the Study of Lung Cancer- Mesothelioma Applied Research Foundation Mesothelioma Clinical Trials Planning Meeting in Bethesda, Maryland. The goal of the meeting was to bring together lead academicians, clinicians, scientists, and the U.S. Food and Drug Administration to focus on the development of clinical trials for patients in whom malignant pleural mesothelioma has been diagnosed. In light of the discovery of new cancer targets affecting the clinical development of novel agents and immunotherapies in malignant mesothelioma, the objective of this meeting was to assemble a consensus on at least two or three practice-changing multimodality clinical trials to be conducted through NCI's National Clinical Trials Network.
Andreas Rimner - One of the best experts on this subject based on the ideXlab platform.
-
radiologic considerations and standardization of malignant pleural mesothelioma imaging within clinical trials consensus statement from the nci thoracic malignancy steering committee international association for the study of lung cancer mesothelioma
Journal of Thoracic Oncology, 2019Co-Authors: Ritu R Gill, Anne S Tsao, Suzanne E Dahlberg, Hedy L Kindler, William G Richards, Samuel G Armato, Roslyn J Francis, Daniel R Gomez, Andreas RimnerAbstract:Detailed guidelines pertaining to radiological assessment of malignant pleural mesothelioma are currently lacking due to the rarity of the disease, complex morphology, propensity to invade multiple planes simultaneously, and lack of specific recommendations within the radiology community about assessment, reporting, and follow-up. In March 2017, a multidisciplinary meeting of mesothelioma experts was co-sponsored by the National Cancer Institute Thoracic Malignancy Steering Committee, International Association for the Study of Lung Cancer, and the Mesothelioma Applied Research Foundation. One of the outcomes of this conference was the foundation of detailed, multidisciplinary consensus imaging and management guidelines. Here, we present the recommendations for radiologic assessment of malignant pleural mesothelioma in the setting of clinical trial enrollment. We discuss optimization of imaging parameters across modalities, standardized reporting, and response assessment within clinical trials.
-
the use of radiation therapy for the treatment of malignant pleural mesothelioma expert opinion from the national cancer institute thoracic malignancy steering committee international association for the study of lung cancer and mesothelioma Applied Research foundation
Journal of Thoracic Oncology, 2019Co-Authors: Daniel R Gomez, Alex A Adjei, Raphael Bueno, Ritu R Gill, Andreas Rimner, Charles B Simone, B John C Cho, Marc De Perrot, David H Harpole, Mary HesdorfferAbstract:Abstract Introduction Detailed guidelines regarding the use of radiation therapy for malignant pleural mesothelioma (MPM) are currently lacking because of the rarity of the disease, the wide spectrum of clinical presentations, and the paucity of high-level data on individual treatment approaches. Methods In March 2017, a multidisciplinary meeting of mesothelioma experts was cosponsored by the U.S. National Cancer Institute, International Association for the Study of Lung Cancer Research, and Mesothelioma Applied Research Foundation. Among the outcomes of this conference was the foundation of detailed, multidisciplinary consensus guidelines. Results Here we present consensus recommendations on the use of radiation therapy for MPM in three discrete scenarios: (1) hemithoracic radiation therapy to be used before or after extrapleural pneumonectomy; (2) hemithoracic radiation to be used as an adjuvant to lung-sparing procedures (i.e., without pneumonectomy); and (3) palliative radiation therapy for focal symptoms caused by the disease. We discuss appropriate simulation techniques, treatment volumes, dose fractionation regimens, and normal tissue constraints. We also assess the role of particle beam therapy, specifically, proton beam therapy, for MPM. Conclusion The recommendations provided in this consensus statement should serve as important guidelines for developing future clinical trials of treatment approaches for MPM.
Anne S Tsao - One of the best experts on this subject based on the ideXlab platform.
-
radiologic considerations and standardization of malignant pleural mesothelioma imaging within clinical trials consensus statement from the nci thoracic malignancy steering committee international association for the study of lung cancer mesothelioma
Journal of Thoracic Oncology, 2019Co-Authors: Ritu R Gill, Anne S Tsao, Suzanne E Dahlberg, Hedy L Kindler, William G Richards, Samuel G Armato, Roslyn J Francis, Daniel R Gomez, Andreas RimnerAbstract:Detailed guidelines pertaining to radiological assessment of malignant pleural mesothelioma are currently lacking due to the rarity of the disease, complex morphology, propensity to invade multiple planes simultaneously, and lack of specific recommendations within the radiology community about assessment, reporting, and follow-up. In March 2017, a multidisciplinary meeting of mesothelioma experts was co-sponsored by the National Cancer Institute Thoracic Malignancy Steering Committee, International Association for the Study of Lung Cancer, and the Mesothelioma Applied Research Foundation. One of the outcomes of this conference was the foundation of detailed, multidisciplinary consensus imaging and management guidelines. Here, we present the recommendations for radiologic assessment of malignant pleural mesothelioma in the setting of clinical trial enrollment. We discuss optimization of imaging parameters across modalities, standardized reporting, and response assessment within clinical trials.
-
current and future management of malignant mesothelioma a consensus report from the national cancer institute thoracic malignancy steering committee international association for the study of lung cancer and mesothelioma Applied Research foundation
Journal of Thoracic Oncology, 2018Co-Authors: Anne S Tsao, Wolf O Lindwasser, Alex A Adjei, Prasad S Adusumilli, Matthew L Beyers, Gideon M Blumenthal, Raphael Bueno, Bryan M Burt, Michele Carbone, Suzanne E DahlbergAbstract:On March 28- 29, 2017, the National Cancer Institute (NCI) Thoracic Malignacy Steering Committee, International Association for the Study of Lung Cancer, and Mesothelioma Applied Research Foundation convened the NCI-International Association for the Study of Lung Cancer- Mesothelioma Applied Research Foundation Mesothelioma Clinical Trials Planning Meeting in Bethesda, Maryland. The goal of the meeting was to bring together lead academicians, clinicians, scientists, and the U.S. Food and Drug Administration to focus on the development of clinical trials for patients in whom malignant pleural mesothelioma has been diagnosed. In light of the discovery of new cancer targets affecting the clinical development of novel agents and immunotherapies in malignant mesothelioma, the objective of this meeting was to assemble a consensus on at least two or three practice-changing multimodality clinical trials to be conducted through NCI's National Clinical Trials Network.
Ritu R Gill - One of the best experts on this subject based on the ideXlab platform.
-
radiologic considerations and standardization of malignant pleural mesothelioma imaging within clinical trials consensus statement from the nci thoracic malignancy steering committee international association for the study of lung cancer mesothelioma
Journal of Thoracic Oncology, 2019Co-Authors: Ritu R Gill, Anne S Tsao, Suzanne E Dahlberg, Hedy L Kindler, William G Richards, Samuel G Armato, Roslyn J Francis, Daniel R Gomez, Andreas RimnerAbstract:Detailed guidelines pertaining to radiological assessment of malignant pleural mesothelioma are currently lacking due to the rarity of the disease, complex morphology, propensity to invade multiple planes simultaneously, and lack of specific recommendations within the radiology community about assessment, reporting, and follow-up. In March 2017, a multidisciplinary meeting of mesothelioma experts was co-sponsored by the National Cancer Institute Thoracic Malignancy Steering Committee, International Association for the Study of Lung Cancer, and the Mesothelioma Applied Research Foundation. One of the outcomes of this conference was the foundation of detailed, multidisciplinary consensus imaging and management guidelines. Here, we present the recommendations for radiologic assessment of malignant pleural mesothelioma in the setting of clinical trial enrollment. We discuss optimization of imaging parameters across modalities, standardized reporting, and response assessment within clinical trials.
-
the use of radiation therapy for the treatment of malignant pleural mesothelioma expert opinion from the national cancer institute thoracic malignancy steering committee international association for the study of lung cancer and mesothelioma Applied Research foundation
Journal of Thoracic Oncology, 2019Co-Authors: Daniel R Gomez, Alex A Adjei, Raphael Bueno, Ritu R Gill, Andreas Rimner, Charles B Simone, B John C Cho, Marc De Perrot, David H Harpole, Mary HesdorfferAbstract:Abstract Introduction Detailed guidelines regarding the use of radiation therapy for malignant pleural mesothelioma (MPM) are currently lacking because of the rarity of the disease, the wide spectrum of clinical presentations, and the paucity of high-level data on individual treatment approaches. Methods In March 2017, a multidisciplinary meeting of mesothelioma experts was cosponsored by the U.S. National Cancer Institute, International Association for the Study of Lung Cancer Research, and Mesothelioma Applied Research Foundation. Among the outcomes of this conference was the foundation of detailed, multidisciplinary consensus guidelines. Results Here we present consensus recommendations on the use of radiation therapy for MPM in three discrete scenarios: (1) hemithoracic radiation therapy to be used before or after extrapleural pneumonectomy; (2) hemithoracic radiation to be used as an adjuvant to lung-sparing procedures (i.e., without pneumonectomy); and (3) palliative radiation therapy for focal symptoms caused by the disease. We discuss appropriate simulation techniques, treatment volumes, dose fractionation regimens, and normal tissue constraints. We also assess the role of particle beam therapy, specifically, proton beam therapy, for MPM. Conclusion The recommendations provided in this consensus statement should serve as important guidelines for developing future clinical trials of treatment approaches for MPM.
